UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Factor XI deficiency

Author
Caroline Bérubé, MD
Section Editor
Lawrence LK Leung, MD
Deputy Editor
Jennifer S Tirnauer, MD

INTRODUCTION

Factor XI (FXI) is a plasma glycoprotein that participates in the contact phase of blood coagulation (ie, the intrinsic pathway). Unlike the other contact factors (ie, high molecular weight kininogen, factor XII, prekallikrein), FXI is important for normal hemostasis in vivo. It plays an important role in the amplification of the initial coagulation response via a positive feedback mechanism for the generation of additional thrombin.

The diagnosis and management of factor XI deficiency are discussed here.

Separate topic reviews discuss other inherited and acquired factor deficiencies, and a general approach to the patient with unexplained bleeding or abnormal coagulation testing:

Unexplained bleeding – (See "Approach to the child with bleeding symptoms" and "Approach to the adult patient with a bleeding diathesis".)

Unexplained prolonged aPTT – (See "Clinical use of coagulation tests".)

                               

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Aug 01 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Tuszynski GP, Bevacqua SJ, Schmaier AH, et al. Factor XI antigen and activity in human platelets. Blood 1982; 59:1148.
  2. von dem Borne PA, Koppelman SJ, Bouma BN, Meijers JC. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost 1994; 72:397.
  3. Ho DH, Badellino K, Baglia FA, et al. The role of high molecular weight kininogen and prothrombin as cofactors in the binding of factor XI A3 domain to the platelet surface. J Biol Chem 2000; 275:25139.
  4. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165.
  5. Podmore A, Smith M, Savidge G, Alhaq A. Real-time quantitative PCR analysis of factor XI mRNA variants in human platelets. J Thromb Haemost 2004; 2:1713.
  6. Gailani D, Zivelin A, Sinha D, Walsh PN. Do platelets synthesize factor XI? J Thromb Haemost 2004; 2:1709.
  7. Ghosh N, Marotta PJ, McAlister VC. Correction of factor XI deficiency by liver transplantation. N Engl J Med 2005; 352:2357.
  8. Soons H, Janssen-Claessen T, Tans G, Hemker HC. Inhibition of factor XIa by antithrombin III. Biochemistry 1987; 26:4624.
  9. Walsh PN, Sinha D, Kueppers F, et al. Regulation of factor XIa activity by platelets and alpha 1-protease inhibitor. J Clin Invest 1987; 80:1578.
  10. Meijers JC, Vlooswijk RA, Bouma BN. Inhibition of human blood coagulation factor XIa by C-1 inhibitor. Biochemistry 1988; 27:959.
  11. Saito H, Goldsmith GH, Moroi M, Aoki N. Inhibitory spectrum of alpha 2-plasmin inhibitor. Proc Natl Acad Sci U S A 1979; 76:2013.
  12. Van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Protease nexin-II (amyloid beta-protein precursor): a platelet alpha-granule protein. Science 1990; 248:745.
  13. Smith RP, Higuchi DA, Broze GJ Jr. Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science 1990; 248:1126.
  14. Badellino KO, Walsh PN. Protease nexin II interactions with coagulation factor XIa are contained within the Kunitz protease inhibitor domain of protease nexin II and the factor XIa catalytic domain. Biochemistry 2000; 39:4769.
  15. Walsh PN. Roles of platelets and factor XI in the initiation of blood coagulation by thrombin. Thromb Haemost 2001; 86:75.
  16. Pedicord DL, Seiffert D, Blat Y. Feedback activation of factor XI by thrombin does not occur in plasma. Proc Natl Acad Sci U S A 2007; 104:12855.
  17. Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science 1991; 253:909.
  18. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266:7353.
  19. Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99:2323.
  20. Bouma BN, Meijers JC. Role of blood coagulation factor XI in downregulation of fibrinolysis. Curr Opin Hematol 2000; 7:266.
  21. Bolton-Maggs PH. Factor XI deficiency--resolving the enigma? Hematology Am Soc Hematol Educ Program 2009; :97.
  22. Thompson RE, Mandle R Jr, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977; 60:1376.
  23. Meijers JC, Davie EW, Chung DW. Expression of human blood coagulation factor XI: characterization of the defect in factor XI type III deficiency. Blood 1992; 79:1435.
  24. Baglia FA, Shrimpton CN, López JA, Walsh PN. The glycoprotein Ib-IX-V complex mediates localization of factor XI to lipid rafts on the platelet membrane. J Biol Chem 2003; 278:21744.
  25. Gailani D, Ho D, Sun MF, et al. Model for a factor IX activation complex on blood platelets: dimeric conformation of factor XIa is essential. Blood 2001; 97:3117.
  26. Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000; 342:696.
  27. Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood 2009; 114:2878.
  28. Eichinger S, Schönauer V, Weltermann A, et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103:3773.
  29. Yang DT, Flanders MM, Kim H, Rodgers GM. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol 2006; 126:411.
  30. Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 2008; 111:4113.
  31. Salomon O, Steinberg DM, Zucker M, et al. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost 2011; 105:269.
  32. Tucker EI, Marzec UM, White TC, et al. Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 2009; 113:936.
  33. Crosby JR, Marzec U, Revenko AS, et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol 2013; 33:1670.
  34. Yau JW, Liao P, Fredenburgh JC, et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 2014; 123:2102.
  35. Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med 2015; 372:232.
  36. Asakai R, Chung DW, Ratnoff OD, Davie EW. Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. Proc Natl Acad Sci U S A 1989; 86:7667.
  37. Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 1991; 325:153.
  38. Kravtsov DV, Wu W, Meijers JC, et al. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood 2004; 104:128.
  39. Kravtsov DV, Monahan PE, Gailani D. A classification system for cross-reactive material-negative factor XI deficiency. Blood 2005; 105:4671.
  40. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study. Thromb Haemost 1995; 73:194.
  41. Ragni MV, Sinha D, Seaman F, et al. Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds. Blood 1985; 65:719.
  42. Abrahamian A, Xi MS, Donnelly JJ, Rockey JH. Effect of interferon-gamma on the expression of transforming growth factor-beta by human corneal fibroblasts: role in corneal immunoseclusion. J Interferon Cytokine Res 1995; 15:323.
  43. Saito H, Ratnoff OD, Bouma BN, Seligsohn U. Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. J Lab Clin Med 1985; 106:718.
  44. Duga S, Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost 2013; 39:621.
  45. www.factorxi.org (Accessed on February 19, 2009).
  46. http://www.isth.org/?MutationsRareBleedin (Accessed on January 02, 2014).
  47. Tavori S, Brenner B, Tatarsky I. The effect of combined factor XI deficiency with von Willebrand factor abnormalities on haemorrhagic diathesis. Thromb Haemost 1990; 63:36.
  48. Sano M, Saito H, Shimamoto Y, et al. Combined hereditary factor XI (plasma thromboplastin antecedent) deficiency, von Willebrand's disease, and xeroderma pigmentosum in a Japanese family. Am J Hematol 1993; 44:129.
  49. Santoro R, Prejanò S, Iannaccaro P. Factor XI deficiency: a description of 34 cases and literature review. Blood Coagul Fibrinolysis 2011; 22:431.
  50. Bérubé C, Ofosu FA, Kelton JG, Blajchman MA. A novel congenital haemostatic defect: combined factor VII and factor XI deficiency. Blood Coagul Fibrinolysis 1992; 3:357.
  51. Berg LP, Varon D, Martinowitz U, et al. Combined factor VIII/factor XI deficiency may cause intra-familial clinical variability in haemophilia A among Ashkenazi Jews. Blood Coagul Fibrinolysis 1994; 5:59.
  52. De Angelis V, Orazi BM, Santarossa L, Molaro G. Combined factor VIII and factor XI congenital deficiency: a case report. Haematologica 1990; 75:272.
  53. Sharland M, Patton MA, Talbot S, et al. Coagulation-factor deficiencies and abnormal bleeding in Noonan's syndrome. Lancet 1992; 339:19.
  54. Bertola DR, Carneiro JD, D'Amico EA, et al. Hematological findings in Noonan syndrome. Rev Hosp Clin Fac Med Sao Paulo 2003; 58:5.
  55. Bolton-Maggs PH, Peretz H, Butler R, et al. A common ancestral mutation (C128X) occurring in 11 non-Jewish families from the UK with factor XI deficiency. J Thromb Haemost 2004; 2:918.
  56. Zivelin A, Bauduer F, Ducout L, et al. Factor XI deficiency in French Basques is caused predominantly by an ancestral Cys38Arg mutation in the factor XI gene. Blood 2002; 99:2448.
  57. Mitchell M, Mountford R, Butler R, et al. Spectrum of factor XI (F11) mutations in the UK population--116 index cases and 140 mutations. Hum Mutat 2006; 27:829.
  58. Shpilberg O, Peretz H, Zivelin A, et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995; 85:429.
  59. Seligsohn U. High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood 1978; 51:1223.
  60. Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344:1773.
  61. Clarkson K, Rosenfeld B, Fair J, et al. Factor XI deficiency acquired by liver transplantation. Ann Intern Med 1991; 115:877.
  62. Salomon O, Zivelin A, Livnat T, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003; 101:4783.
  63. Zucker M, Zivelin A, Teitel J, Seligsohn U. Induction of an inhibitor antibody to factor XI in a patient with severe inherited factor XI deficiency by Rh immune globulin. Blood 2008; 111:1306.
  64. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10:615.
  65. Rugeri L, Quélin F, Chatard B, et al. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia 2010; 16:771.
  66. Setty S, Reddell A, England A, et al. The role of recombinant factor VIIa for obstetric block in women with severe factor XI deficiency. Haemophilia 2011; 17:906.
  67. Riddell A, Abdul-Kadir R, Pollard D, et al. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost 2011; 106:521.
  68. Lazzerini PE, Capecchi PL, Nizzi C, et al. Cerebellar haemorrhage, factor XI deficiency and concomitant risk factors. QJM 2015; 108:829.
  69. Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006; 12:490.
  70. Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, et al. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988; 69:521.
  71. Kitchens CS. Factor XI: a review of its biochemistry and deficiency. Semin Thromb Hemost 1991; 17:55.
  72. Kadir RA, Lee CA, Sabin CA, et al. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br J Obstet Gynaecol 1998; 105:314.
  73. Salomon O, Steinberg DM, Tamarin I, et al. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005; 16:37.
  74. Chi C, Kulkarni A, Lee CA, Kadir RA. The obstetric experience of women with factor XI deficiency. Acta Obstet Gynecol Scand 2009; 88:1095.
  75. Myers B, Pavord S, Kean L, et al. Pregnancy outcome in Factor XI deficiency: incidence of miscarriage, antenatal and postnatal haemorrhage in 33 women with Factor XI deficiency. BJOG 2007; 114:643.
  76. Arun B, Kessler C. Clinical Manifestations and Therapy of the Hemophilias. In: Hemostasis and Thrombosis, Basic Principles and Clinical Practice, 4th ed, Colman R, Hirsh J, Marder V, et al. (Eds), Lippincott Williams and Wilkins, Philadelphia 2001. p.822.
  77. Santoro C, Goldberg I, Bridey F, et al. Successful hip arthroplasty in an adult male with severe factor XI deficiency using Hemoleven®, a factor XI concentrate. Haemophilia 2011; 17:777.
  78. Bolton-Maggs PH, Colvin BT, Satchi BT, et al. Thrombogenic potential of factor XI concentrate. Lancet 1994; 344:748.
  79. Mannucci PM, Bauer KA, Santagostino E, et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994; 84:1314.
  80. Richards EM, Makris MM, Cooper P, Preston FE. In vivo coagulation activation following infusion of highly purified factor XI concentrate. Br J Haematol 1997; 96:293.
  81. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10:593.
  82. Bolton-Maggs P, Goudemand J, Hermans C, et al. FXI concentrate use and risk of thrombosis. Haemophilia 2014; 20:e349.
  83. Bauduer F, de Raucourt E, Boyer-Neumann C, et al. Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study. Haemophilia 2015; 21:481.
  84. Bauduer F, Bendriss P, Freyburger G, et al. Use of desmopressin for prophylaxis of surgical bleeding in factor XI-deficient patients. Acta Haematol 1998; 99:52.
  85. Castaman G, Ruggeri M, Rodeghiero F. Clinical usefulness of desmopressin for prevention of surgical bleeding in patients with symptomatic heterozygous factor XI deficiency. Br J Haematol 1996; 94:168.
  86. Franchini M, de Gironcoli M, Lippi G, et al. Prophylactic use of desmopressin in surgery of six patients with symptomatic heterozygous factor XI deficiency. Haematologica 2000; 85:106.
  87. White B, Lawler P, Riddell A, et al. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease. Br J Haematol 2004; 126:100.
  88. Billon S, Le Niger C, Escoffre-Barbe M, et al. The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant. Blood Coagul Fibrinolysis 2001; 12:551.
  89. Hedner U. Factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis 1990; 1:307.
  90. Lawler P, White B, Pye S, et al. Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency. Haemophilia 2002; 8:145.
  91. O'connell NM. Factor XI deficiency. Semin Hematol 2004; 41:76.
  92. Salomon O, Zivelin A, Livnat T, Seligsohn U. Inhibitors to Factor XI in patients with severe Factor XI deficiency. Semin Hematol 2006; 43:S10.
  93. Livnat T, Tamarin I, Mor Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102:487.
  94. Schulman S, Németh G. An illustrative case and a review on the dosing of recombinant factor VIIa in congenital factor XI deficiency. Haemophilia 2006; 12:223.
  95. Brown SA. What dose of recombinant activated factor VII should be used in patients with factor XI deficiency? Haemophilia 2005; 11:430.
  96. Berliner S, Horowitz I, Martinowitz U, et al. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinolysis 1992; 3:465.
  97. Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization. Haemophilia 2006; 12:301.